VERAXA Biotech (NASDAQ: VRXA) has entered into a collaboration with Ardigen S.A., an AI-driven bioinformatics company, to support the development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership aims to develop AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to enhance tumor targeting while reducing off-target toxicity.
The integration of artificial intelligence into VERAXA’s research and development strategy is expected to improve target selection by analyzing large preclinical and clinical datasets, including programs that showed efficacy but failed due to toxicity. According to VERAXA, this collaboration could strengthen the development of precision oncology therapies and improve long-term drug development success rates. The company believes that AI-driven insights will help in identifying the most promising targets and combinations, potentially accelerating the pipeline and increasing the probability of clinical success.
VERAXA’s BiTAC platform focuses on bispecific T-cell engagers that recruit T-cells to attack cancer cells. By refining target selection through AI, the company hopes to develop therapies that are both more effective and safer. The collaboration with Ardigen, known for its expertise in bioinformatics and AI, represents a strategic move to leverage computational tools in the complex field of immunotherapy.
For more details, the full press release is available at https://ibn.fm/GLFg2. VERAXA Biotech is dedicated to building a premier engine for discovering and developing next-generation antibody-based therapeutics, including bispecific T-cell engagers and bispecific ADCs. The company was founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL).
This collaboration underscores a broader trend in the biopharmaceutical industry where AI is increasingly used to streamline drug development, reduce costs, and improve success rates. By applying AI to its BiTAC platform, VERAXA aims to address some of the key challenges in oncology, such as identifying effective target combinations and minimizing toxicity. The company’s forward-looking statements indicate that while risks and uncertainties remain, the integration of AI could be a pivotal step in advancing its pipeline.
Investors and stakeholders can find the latest news and updates regarding VRXA in the company’s newsroom at https://ibn.fm/VRXA. Forward-looking statements in this article involve risks and uncertainties, including those detailed in VERAXA’s filings with the SEC. The company undertakes no duty to update this information unless required by law.
